EBV-Specific TCR Gene Transfer for Targeted Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating EBV-associated diseases, such as adoptive T cell immunotherapy, are labor-intensive and expensive, and often insufficient in generating sufficient T cells specific for target cells.
Innovation Solution
Development of T-cell receptors (TCRs) with specific complementarity determining regions (CDRs) that recognize epitopes derived from EBV latent membrane proteins LMP1 and LMP2, allowing for the production of EBV-specific T cells for targeted therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adoptive T cell immunotherapy is used to treat EBV-associated diseases, then treatment efficacy is improved, but treatment cost and labor intensity increase significantly
Solution Approach 1:
The patent extracts and isolates specific TCR genes (TRAC and TRBC) that are responsible for EBV antigen recognition. By separating these functional gene components from the complex T cell generation process, the invention enables direct genetic transfer to generate EBV-specific T cells, thereby simplifying the overall treatment protocol while maintaining efficacy
Solution Approach 2:
The patent performs preliminary identification and characterization of specific TCR sequences that recognize EBV antigens (LMP1, LMP2, EBNA1) before clinical application. This advance preparation of validated TCR genes allows for streamlined therapeutic implementation without requiring complex in vitro T cell expansion protocols
2Quantity of substance
If in vitro expansion of EBV-specific CTLs is performed to increase T cell numbers, then sufficient target-specific T cells are obtained, but treatment cost and time requirements increase
Solution Approach 1:
The patent performs preliminary optimization of TCR gene sequences for efficient expression and functional activity before transfer. This advance preparation ensures that transferred TCR genes immediately produce functional EBV-specific T cells without requiring lengthy in vitro expansion periods
Solution Approach 2:
The patent uses genetic copying by transferring TCR gene sequences into target T cells, creating precise replicas of the desired EBV-specific T cell phenotype. This genetic copying approach is more efficient than phenotypic expansion methods, as it directly programs the desired specificity rather than requiring gradual selection and expansion
3Adaptability or versatility
If TCR diversity is increased through V-D-J rearrangement to recognize more antigens, then antigen recognition capability is improved, but T cell development complexity and potential autoreactivity increase
Solution Approach 1:
The patent focuses on optimizing specific local regions of the TCR, particularly the CDR3 domains which are responsible for antigen contact. By concentrating diversity generation in these critical local regions through targeted V-D-J rearrangement, the invention achieves broad antigen recognition while maintaining overall TCR structure simplicity and thymic selection efficiency
Solution Approach 2:
The patent identifies TCR sequences that can recognize multiple EBV antigens (LMP1, LMP2, EBNA1) through a single receptor configuration. This multi-functional TCR design broadens antigen coverage without requiring separate TCR variants for each antigen, thereby simplifying the overall system
Data Source
AI summary
Provided herein are isolated alpha and beta chains of a T-cell receptor (TCR) that is specific for an EBV antigen. Also described herein are TCRs having said alpha and beta chains and methods of making and using same, such as cellular immunotherapy in subjects having an EBV-associated disease, disorder or condition.